Cyteir Therapeutics, Inc.

Revenue was not reported. Research and development expenses were $8.3 million in Q4 2021 versus $3.9 million in Q4 2020, and $31 million for full-year 2021 versus $16.8 million in full-year 2020. General and administrative expenses were $3.6 million in Q4 2021 versus $1.5 million a year earlier, and $11.3 million for full-year 2021 versus $4.2 million in 2020. Net loss was $11.8 million, or $0.34 per share, in Q4 2021 versus $5.4 million, or $2.92 per share, in Q4 2020; full-year net loss was $42.1 million, or $2.16 per share, versus $20.8 million, or $13.60 per share. Net cash used in operating activities was $36 million in 2021. The company ended 2021 with $189.7 million in cash and cash equivalents and said its current capital resources are expected to fund operations into 2024. No formal revenue or EPS guidance was given; management guided to multiple 2022 data readouts, including interim data from six monotherapy Phase 2 cohorts and safety data from three combination cohorts before year-end.

Markus Renschler framed 2021 as a year of execution, saying the company met key clinical objectives from its IPO and moved CYT-0851 into later-stage development. He emphasized the drug’s early clinical proof-of-concept, its differentiated tolerability, and the potential to broaden into earlier lines of therapy if efficacy continues to hold up. His tone was optimistic but still cautious, repeatedly noting the program is early and that more data are needed.

Dave Gaiero focused on the cost structure and balance sheet. He said R&D rose to $8.3 million in Q4 and $31 million for the year, while G&A rose to $3.6 million in Q4 and $11.3 million for the year, driven by clinical activity, headcount, and public-company costs. He noted 2021 operating cash use of $36 million, expects cash burn to increase as trials and preclinical work expand, and said $189.7 million in cash should fund operations into 2024.

Analysts mainly pressed on timing and what the upcoming data would show. Management confirmed the June abstract would update the earlier monotherapy dose-escalation data, while the six monotherapy expansion cohorts and three combination cohorts would be read out in the second half of 2022, with safety the primary focus but efficacy signals possible. They also said enrollment slowed in January because of Omicron-related site staffing and patient issues but improved by mid-February and was back on track in March; the study is open at 18 U.S. sites.